Announcements Trials
Browse Landscape

Phase

Phase 1/2 3

Status

Recruiting 3Terminated 2Suspended 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Thoracic 2Gynecologic 2Dermatologic 2Sarcoma 1Other solid neoplasm 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Melanoma 7Leukemia, Myeloid, Acute 6Breast Neoplasms 6Colorectal Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Ovarian Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Skin Neoplasms 3Mesothelioma, Malignant 3Lymphoma, Non-Hodgkin 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Stomach Neoplasms 2Sarcoma 2Recurrence 2Rectal Neoplasms 2Pleural Effusion, Malignant 2Neuroblastoma 2Neoplasms 2Multiple Myeloma 2Lung Neoplasms 2Leukemia, Myeloid 2Leukemia 2Head and Neck Neoplasms 2Glioblastoma 2Esophageal Neoplasms 2Carcinoma, Merkel Cell 2Urinary Bladder Neoplasms 1Turcot syndrome 1

Interventions

pembrolizumab 57Carboplatin 34Paclitaxel 24Cyclophosphamide 23Capecitabine 18sacituzumab govitecan 16Specimen Handling 15130-nm albumin-bound paclitaxel 15toripalimab 11Drug Therapy 11Biopsy 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Taxes 9Epirubicin 9durvalumab 8Albumin-Bound Paclitaxel 8olaparib 7camrelizumab 7Gemcitabine 7Doxorubicin 7Docetaxel 7fludarabine 6famitinib 5Nivolumab 5Injections 5atezolizumab 4abemaciclib 4Trastuzumab 4Standard of Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Triple Negative Breast Neoplasms × Interleukin-2 × Clear all
NCT05296564 2025-10-02

Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers

Hadassah Medical Organization

Phase 1/2 Recruiting
3 enrolled
BreastCNSDermatologicGynecologicSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Sarcoma, Synovial, Triple Negative Breast Neoplasms

NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06532812 2024-11-12

BAH249

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡